Publications

  1. Meagher KM. Why We Should Reexamine the "Golden Age" of Antibiotics in Social Context. AMA J Ethics. 2024 May 1; 26 (5):E418-428 Epub 2024 May 01
    View PubMed
  2. Meagher KM. Can One Health Policy Help Us Expand an Ethics of Interconnection and Interdependence? AMA J Ethics. 2024 Feb 1; 26 (2):E162-170 Epub 2024 Feb 01
    View PubMed
  3. Chipman SA, Meagher K, Barwise AK. A Public Health Ethics Framework for Populations with Limited English Proficiency. Am J Bioeth. 2023 Jun 28; 1-16 Epub 2023 June 28
    View PubMed
  4. Meagher KM, Watson S, Suh GA, Virk A. The New Precision Stewards? J Pers Med. 2022 Aug 12; 12 (8)
    View PubMed
  5. Meagher KM, Finn KS, Stuttgen Finn K, Curtis SH, Borucki J, Beck AT, Cheema AW, Sharp RR. Lay understandings of drug-gene interactions: The right medication, the right dose, at the right time, but what are the right words? Clin Transl Sci. 2022 Mar; 15 (3):721-731 Epub 2021 Nov 25
    View PubMed
  6. Conley JM, Davis A, Henderson GE, Meagher K, Cadigan RJ, Juengst EJ, Walker RL, Waltz M. A New Governance Approach to Regulating Human Genome Editing (April 8, 2021).Available at SSRN UNC Legal Studies Research Paper. 4/9/21.
  7. Barwise AK, Thorsteinsdottir B, Allyse MA, Clarke MJ, Meagher KM. Bioethics Advocacy in Ethos, Practice and Metrics. Am J Bioeth 2021 Feb; 21 (2):69-72
    View PubMed
  8. Meagher KM, Curtis SH, Borucki S, Beck A, Srinivasan T, Cheema A, Sharp RR. Communicating unexpected pharmacogenomic results to biobank contributors: A focus group study. Patient Educ Couns. 2021 Feb; 104 (2):242-249 Epub 2020 Sept 02
    View PubMed
  9. Lapid MI, Meagher KM, Giunta HC, Clarke BL, Ouellette Y, Armbrust TL, Sharp RR, Wright RS. Ethical Challenges in COVID-19 Biospecimen Research: Perspectives From Institutional Review Board Members and Bioethicists. Mayo Clin Proc. 2021 Jan; 96 (1):165-173 Epub 2020 Oct 23
    View PubMed
  10. Conley JM, Davis AM, Henderson GE, Juengst ET, Meagher KM, Walker RL, Waltz M, Cadigan J. A New Governance Approach to Regulating Human Genome Editing. N C J Law Technol. 2020 Dec; 22 (2):107-141
    View PubMed
  11. Henderson GE, Rennie S, Corneli A, Meagher K, Cadigan RJ, Kroon E, Ananworanich J, Peay HL. Parallel but connected: Nuances of conducting behavioral and social science research alongside ethically challenging HIV remission trials. Contemp Clin Trials Commun. 2020 Sep; 19:100594 Epub 2020 June 16
    View PubMed
  12. Meagher KM, Cummins NW, Bharucha AE, Badley AD, Chlan LL, Wright RS. COVID-19 Ethics and Research. Mayo Clin Proc. 2020 Jun; 95 (6):1119-1123 Epub 2020 Apr 24
    View PubMed
  13. Waltz M, Meagher KM, Henderson GE, Goddard KA, Muessig K, Berg JS, Weck KE, Cadigan RJ. Assessing the implications of positive genomic screening results. Per Med. 2020 Mar; 17 (2):101-109 Epub 2020 Mar 03
    View PubMed
  14. Meagher KM, Allyse MA, Master Z, Sharp RR. Reexamining the Ethics of Human Germline Editing in the Wake of Scandal. Mayo Clin Proc. 2020 Feb; 95 (2):330-338
    View PubMed
  15. Meagher KM, Curtis SH, Gamm KO, Sutton EJ, McCormick JB, Sharp RR. At a Moment's Notice: Community Advisory Board Perspectives on Biobank Communication to Supplement Broad Consent. Public Health Genomics. 2020; 23 (3-4):77-89 Epub 2020 May 12
    View PubMed
  16. Olson JE, Ryu E, Hathcock MA, Gupta R, Bublitz JT, Takahashi PY, Bielinski SJ, St Sauver JL, Meagher K, Sharp RR, Thibodeau SN, Cicek M, Cerhan JR. Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile. BMJ Open. 2019 Nov 6; 9 (11):e032707 Epub 2019 Nov 06
    View PubMed
  17. Corneli A, Meagher K, Henderson G, Peay H, Rennie S. How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS Behav. 2018 Dec 10 [Epub ahead of print]
    View PubMed
  18. Henderson GE, Waltz M, Meagher K, Cadigan RJ, Jupimai T, Isaacson S, Ormsby NQ, Colby DJ, Kroon E, Phanuphak N, Ananworanich J, Peay HL. Going off antiretroviral treatment in a closely monitored HIV "cure" trial: longitudinal assessments of acutely diagnosed trial participants and decliners. J Int AIDS Soc. 2019 Mar; 22 (3):e25260
    View PubMed
  19. Juengst ET, Henderson GE, Walker RL, Conley JM, MacKay D, Meagher KM, Saylor K, Waltz M, Kuczynski KJ, Cadigan RJ. Is Enhancement the Price of Prevention in Human Gene Editing? CRISPR J. 2018 Dec; 1:351-354 Epub 2018 Nov 26
    View PubMed
  20. Meagher KM, Berg JS. Too much of a good thing? Overdiagnosis, or overestimating risk in preventive genomic screening. Per Med. 2018 Sep; 15 (5):343-346 Epub 2018 Sept 27
    View PubMed
  21. Meagher KM, McGowan ML, Settersten RA Jr, Fishman JR, Juengst ET. Precisely Where Are We Going? Charting the New Terrain of Precision Prevention. Annu Rev Genomics Hum Genet. 2017 Aug 31; 18:369-387 Epub 2017 Apr 24
    View PubMed
  22. Henderson GE, Peay HL, Kroon E, Cadigan RJ, Meagher KM, Jupimai T, Gilbertson A, Fisher J, Ormsby NQ, Chomchey N, Phanuphak N, Ananworanich J, Rennie S. Ethics of treatment interruption trials in HIV cure research: Addressing the conundrum of risk/benefit assessment Journal of Medical Ethics. 2017.
  23. Meagher KM, Lee LM. Public health perspectives and Ethical, Legal, and Social Issues: Integrating public health and public bioethics. Public Health Reports. 2016; 131(1):44-51.
  24. Meagher KM, Spector-Bagdady K. Present lessons from past infractions: STD research in Guatemala in the 1940s as an ethics case study Teaching Ethics. 2014; 14(2):53-76.
  25. Meagher KM. Considering virtue: Public health and clinical ethics Journal of Evaluation in Clinical Practice. 2011; 17(5):888-893.
  26. Campo-Engelstein L, Meagher KM. Costa Rica's white legend: How racial narratives undermind the values of its health care system. Developing World Bioethics. 2011; 11(2):9-107.